On 5 December 2017, the Agency’s Committee for Risk Assessment (‘RAC’) adopted its opinion [https://echa.europa.eu/documents/10162/737bceac-35c3-77fb-ba7a-0e417a81aa4a] concluding that the proposed restriction, as modified by RAC, is the most appropriate Union-wide measure to address the identified risks arising from exposure to these substances in terms of effectiveness in reducing those risks. Moreover, it considered that the implementation of the modified proposed restriction would reduce as well the number of diisocyanate-related cases of dermatitis.
Recital 4, Regulation (EU) 2020/1149
In forcesince 3 Aug 2020